Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Mol Med (Berl) ; 91(10): 1207-20, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23744108

ABSTRACT

UNLABELLED: Gap junctions (GJs) enable intercellular communication between adjacent cells through channels of connexins. Using a three-dimensional construct, we previously showed that endothelial and tumor cells formed GJs, allowing melanoma-specific T lymphocytes to recognize and kill melanoma-derived endothelial cells. We demonstrate here on histological sections of melanoma biopsies that GJ formation occurs in vivo between tumor and endothelial cells and between T lymphocytes and target cells. We also show an in vitro increase of GJ formation in melanoma and endothelial cells following dacarbazin and interferon gamma (IFN-γ) treatment or hypoxic stress induction. Our data indicate that although connexin 43 (Cx43), the main GJ protein of the immune system, was localized at the immunological synapse between T lymphocyte and autologous melanoma cells, its over-expression or inhibition of GJs does not interfere with cytotoxic T lymphocyte (CTL) clone lytic function. In contrast, we showed that inhibition of GJs by oleamide during stimulation of resting PBMCs with Melan-A natural and analog peptides resulted in a decrease in antigen (Ag) specific CD8(+) T lymphocyte induction. These Ag-specific CD8(+) cells displayed paradoxically stronger reactivity as revealed by CD107a degranulation and IFN-γ secretion. These findings indicate that Cx43 does not affect lytic function of differentiated CTL, but reveal a major role for GJs in the regulation of antigen CD8(+)-naïve T lymphocyte activation. KEY MESSAGE: GJ formation occurs in vivo between T lymphocytes and tumor cells Cx43 localized at the immunological synapse between T and autologous melanoma cells Inhibition of GJs resulted in a decrease in Ag-specific CD8(+) T lymphocyte induction A role for GJs in the regulation of antigen CD8(+)-naïve T lymphocyte activation.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Gap Junctions/immunology , MART-1 Antigen/immunology , Melanoma/immunology , Antineoplastic Agents, Alkylating/pharmacology , Apoptosis/genetics , Apoptosis/immunology , Cell Line, Tumor , Connexin 43/genetics , Connexin 43/metabolism , Cytotoxicity, Immunologic/genetics , Dacarbazine/pharmacology , Gap Junctions/drug effects , Gap Junctions/metabolism , Gene Expression , Humans , Hypoxia , Immunological Synapses/metabolism , Interferon-gamma/pharmacology , Melanoma/genetics , Melanoma/metabolism , Oxidative Stress , Protein Transport , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/metabolism
2.
Blood ; 118(12): 3254-62, 2011 Sep 22.
Article in English | MEDLINE | ID: mdl-21803852

ABSTRACT

A major issue in immunosuppressive biotherapy is the use of mesenchymal stem cells (MSCs) that harbor regulatory capacity. However, currently used bone marrow-derived MSCs (BM-MSCs) are short-lived and cannot assure long lasting immunoregulatory function both in vitro and in vivo. Consequently, we have generated MSCs from human induced pluripotent stem (IPS-MSCs) cells that share similar properties with embryonic stem cells (ES-MSCs). Herein, we compared the immunoregulatory properties of ES/IPS-MSCs with those of BM-MSCs and showed, for the first time, that IPS-derived MSCs display remarkable inhibition of NK-cell proliferation and cytolytic function in a similar way to ES-MSCs. Both MSCs disrupt NK-cell cytolytic machinery in the same fashion that BM-MSCs, by down-regulating the expression of different activation markers and ERK1/2 signaling, leading to an impairment to form immunologic synapses with target cells and, therefore, secretion of cytotoxic granules. In addition, they are more resistant than adult BM-MSCs to preactivated NK cells. IPS-MSCs could represent an attractive alternative source of immunoregulatory cells, and their capacity to impair NK-cell cytotoxicity constitutes a complex mechanism to prevent allograft rejection.


Subject(s)
Bone Marrow/immunology , Embryonic Stem Cells , Hematopoietic Stem Cells/immunology , Induced Pluripotent Stem Cells , Killer Cells, Natural/metabolism , Mesenchymal Stem Cells , Signal Transduction/immunology , Amniotic Fluid/cytology , Cell Differentiation , Cell Proliferation , Cell Separation , Cells, Cultured , Down-Regulation , Embryonic Stem Cells/cytology , Embryonic Stem Cells/immunology , Flow Cytometry , Graft Rejection/prevention & control , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/cytology , Humans , Induced Pluripotent Stem Cells/cytology , Induced Pluripotent Stem Cells/immunology , Killer Cells, Natural/cytology , Killer Cells, Natural/immunology , Lentivirus , Lymphocyte Activation/immunology , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/immunology , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Transduction, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...